Liminatus Pharma, Inc. Class A Common Stock

LIMN · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$805$434$5,048$336
Short-Term Investments$0$0$0$0
Receivables$6$945$100$1
Inventory$0$0$0$0
Other Curr. Assets$2-$1,168-$4,787$84
Total Curr. Assets$813$211$361$422
Property Plant & Equip (Net)$0$1$1$0
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$2,016$4,291$15,128$276,017
Tax Assets$0$0$0$0
Other NC Assets$0-$1-$1$0
Total NC Assets$2,016$4,291$15,128$276,017
Other Assets$0$0$0$0
Total Assets$2,829$4,502$15,488$276,439
Liabilities
Payables$1,484$933$508$419
Short-Term Debt$5,122$16,050$16,500$90
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$2,075-$11,824-$13,417$871
Total Curr. Liab.$8,681$5,159$3,591$1,380
LT Debt$0$0$0$0
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$10,017$10,036$10,603$20,190
Total NC Liab.$10,017$10,036$10,603$20,190
Other Liabilities$0$0$0$0
Cap. Leases$0$0$0$0
Total Liabilities$18,699$15,195$14,194$21,570
Equity
Pref Stock$0$0$0$0
Common Stock$1,757$4,050$15,128$276,001
Retained Earnings-$17,518-$14,883-$13,974-$21,132
AOCI-$161$0$0$0
Other Equity$52$140$140$0
Total Equity-$15,870-$10,693$1,294$254,869
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$2,829$4,502$15,488$276,439
Net Debt$4,318$15,616$11,452-$246